Author:
Deppert Wolfgang,Tolstonog Genrich
Reference77 articles.
1. Adhikari AS, Iwakuma T (2009) Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications. Fukuoka Igaku Zasshi 100:217–228
2. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB, Varley JM (2001) Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20:4621–4628
3. Blackburn AC, Brown JS, Naber SP, Otis CN, Wood JT, Jerry DJ (2003) BALB/c alleles for Prkdc and Cdkn2a interact to modify tumor susceptibility in Trp53+/− mice. Cancer Res 63:2364–2368
4. Blackburn AC, Jerry DJ (2002) Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer? Breast Cancer Res 4:101–111
5. Blackburn AC, McLary SC, Naeem R, Luszcz J, Stockton DW, Donehower LA, Mohammed M, Mailhes JB, Soferr T, Naber SP et al (2004) Loss of heterozygosity occurs via mitotic recombination in Trp53+/− mice and associates with mammary tumor susceptibility of the BALB/c strain. Cancer Res 64:5140–5147